

References

I-122

1. Dyax Corp. Kalbitor® [ecallantide] package insert. Burlington, MA 01803. Last accessed September 2014.
2. Farrell C, Hayes S, Relan A, et al. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. *B J Clin Pharmacol*. 2013;(76)6:907.
3. Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. *Allergy Asthma Clin Immunol*. 2014;10(1):50
4. Practice Parameters (JTFPP). The American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma & Immunology (ACAAI), the Joint Counsel of Allergy, Asthma and Immunology. Last accessed March 2015.
5. Caccia S, Suffritti C, Cicardi M. Pathophysiology of hereditary angioedema. *Pediatr Allergy Immunol Pulmolog*. 2014;27(4):159-163
6. Federal Drug Administration. Vaccines, Blood & Biologics: CINRYZE product Information 2015. Zuraw B, Busse P, White M, et al. Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema. *N Engl J Med* 2010;363:513-522.
7. Zuraw B, Banerji A, Bernstein J, et al. U.S. Hereditary Angioedema Association (US HAE) Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. *J Allergy Clin Immunol*. 2013;1(5):458-467.
8. Zuraw BL, Bernstein JA, Lang DM, et al. American Academy of Allergy, Asthma & Immunology (AAAAI); American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. *J Allerg Clin Immunol*. 2013;131(6):1491-1493.
9. CSL Behring LLC. Berinert. C1 esterase inhibitor (human). U.S. Package Insert. Kankakee, IL: CSL Behring; revised November 2009, revised February, 2014.
10. Pham H, Santucci S, Yang W. Successful use of daily intravenous infusion of C1 esterase inhibitor concentrate in the treatment of a hereditary angioedema patient with ascites, hypovolemic shock, sepsis, renal and respiratory failure. *Allergy, Asthma & Clinical Immunology*. 2014; 10(1):62.
11. Schneider L, Hurewitz D, Wasserman R, et al. C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the International Multicenter Prospective Angioedema C1-INH Trials (I.M.P.A.C.T.) studies. *Pediatric Allergy and Immunology*. 2013;24: 54–60.
12. Shire Orphan Therapies, Inc. Firazyf (icatibant) Injection, for subcutaneous use. Prescribing Information. Lexington, MA: Shire Orphan Therapies; August 2013.
13. Boccon-Gibod I, Bouillet L. Safety and efficacy of icatibant self-administration for acute hereditary angioedema. *Clin Exper Immun*. 2012;168(3):303-307.
14. Maurer M, Aberer W, Bouillet L, Caballero T, Fabien V, et al hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. *PLoS ONE*. 2013;(10):137.

15. Santarus, Inc. Ruconest® [C1 esterase inhibitor, recombinant] package insert Raleigh, NC; July 2014.
16. CSL Behring LLC. Berniert® [C1 Esterase Inhibitor (Human)] package insert. Kankakee, IL 60901. October 2009. Revised 7/2016.
17. C1 Esterase Inhibitor [Human] (Cinryze®), for intravenous use [package insert]. Lexington, MA. Shire ViroPharma Inc. Revised 07/2018.
18. Shire Orphan Therapies, Inc. FIRAZYR® [icatibant] package insert. 300 Shire Way Lexington, MA 0242. Revised 12/2015.
19. Rubinstein E, Stolz L, Sheffer A, et al. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency. *BMC Gastroenterology* 2014;14:71.
20. MacGinnite A. Pediatric hereditary angioedema. *Pediatr Allergy Immunol.* 2014;25(5):420–427.
21. Malbran A, Riedl M, Ritchie B, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. *Clin Exp Immunol.* 2014;177(2):544–553.
22. Henao M, Kraschnewski J, Kelbel T, et al. Diagnosis and screening of patients with hereditary angioedema in primary care. *Ther Clin Risk Manag.* 2016;12:701-711.
23. Moellman J, Berstein J, Lindsell C. A consensus parameter for the evaluation and management of angioedema in the emergency department. *Acad Emerg Med.* 2014 ;21(4):469–484.
24. Bernstein J, Riedl M, Zacek L. Facilitating home-based treatment of hereditary angioedema. *Allergy Asthma Proc.* 2015;36:92-99.
25. U.S. Hereditary Angioedema Association. (haea). US hereditary angioedema association medical advisory board 2013 recommendations for the management of hereditary angioedema due to c1 inhibitor deficiency. Accessed April 13, 2017.
26. Henry, H, Kaliner M. Angioedema Treatment & Management. *Medscape.* Last updated April 12, 2017. Histaminergic Angioedema (IH-AAE).
27. Bernstein JA, Riedl M, Zacek L. Facilitating home-based treatment of hereditary angioedema. *Allergy Asthma Proc.* 2015;92-99.
28. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare.* 2016.
29. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
30. MCG™ Care Guidelines, 21st edition, 2017, Home Infusion Therapy, CMT: CMT-0009(SR).
31. MICROMEDEX®SOLUTIONS Compendia. 2017. C1 Esterase Inhibitor, Human.
32. MICROMEDEX®SOLUTIONS Compendia. 2017. Icatibant Acetate.
33. MICROMEDEX®SOLUTIONS Compendia. 2017. Ecallantide.
34. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. C1 Inhibitor, Human.

35. Lanadelumab-flyo (TAKHZYRO™) injection, for subcutaneous use. Lexington, MA. Dyax Corp. Revised 08/2018.
36. Micromedex®Solutions Compendia. Lanadelumab-flyo (TAKHZYRO). 2018.
37. Hayes Inc. Prognosis Overview. Takhzyro (lanadelumab-flyo) for Hereditary Angioedema (HAE). August 2018. Accessed August 28, 2018.